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In 	peri-operative anesthetic practice,
complications occur frequently but are
rapidly identified and abated by astute
clinicians. Rarely, unexpected
complications such as MH develop and
require emergency intervention to
diminish the probability of mortality.
Malignant hyperthermia is a potentially
lethal	 hypermetabolic complication of a
rare inherited muscle disorder	 which is 
caused by inhaled volatile anesthetics
and neuromuscular blocking agents.
(McCance & Huether,	 2010,	 p.	 500).	 
Understanding the susceptibility, risk
factors, 	pathophysiology, 	and 	treatment 
are	 foundational for the	 advanced 
practice nurse developing his practice,
but all clinicians must be knowledgeable
about MH so that evidenced-based 
treatment	 may be swiftly implemented.
Quantifying MH events is challenging, but
that	 the prevalence for MH is 1 in
100,000	 which differs from MH 
susceptibility (MHS) of between 1	 in 
1,200	 and 1	 in 1,300	 which may be
explained by sub-clinical manifestations
of MH crises. (Belani et al., 2020, p. 553) 
Genetics 
Risk Factors 
(Nagelhout &	 Elisha, 2017, p. 775) 
• Known MH susceptibility	 
• Providers must use plain language 
and consider healthcare	 literacy
when obtaining pre-operative 
• Family history of unexpected
intraoperative complications or
death 
• Family history of MH or MH-like
response to anesthesia 
Genetics 
• Caffeine Halothane Contracture 
Test is a muscle biopsy test for 
establishing MHS (MHS) and is the	
gold standard currently (Belani et
al., 2020) 
• Other genetic testing methods such
as next-generation sequencing	 are 
being investigated to rule out MHS
but genetic counseling and CHCT




• Inherited 	autosomal 	dominant 
trait, more than 80 genetic defects
associated with MH (Spruce, 2020,
p. 282) 
• Genetic mutation RYR1 encodes 
ryanodine receptors, CACNA1S
encodes dihydropyridine	 calcium
channels in skeletal muscle 
(Nagelhout &	 Elisha, 2017, p. 774) 
• Reduced magnesium ion affinity
responsible for	 closing calcium
channels and triggering agents
greatly open RYRI channels leading	
to uncontrolled, unopposed 
calcium release from the 
sarcoplasmic reticulum (Belani et
al., 2020, p. 553) 
• Sustained muscle contraction 
consumes adenosine triphosphate 




intracellular contents (potassium, 
CPK, and myoglobin into
circulation”	 (Schneiderbanger,	 
2014, n.p.)	 
• Triggering agents include volatile






Reversing the MH Process
(Hopkins et al., 2021, p. 659) 
• Eliminate the agent (turn off/remove 
vaporizer 
• Administer 100% Oxygen, maximal 
flow 
• Increase 	minute 	ventilation 	2-3x 
normal 
• Insert 	activated 	charcoal 	filters 	into 
inspiratory and expiratory limbs of
the circuit 
• Administer dantrolene sodium, 2.5	 
mg/kg as frequently as needed until a 
decrease in ETCO2, decreased	 muscle
rigidity, and lowering heart rate are
appreciated (MHAUS, 2021) 
• Initiate 	active 	body 	cooling 
• Supportive therapy for other 
symptoms 
• When body temperature rises above
41° C, DIC	 is the most common cause
of death	 (Gong, 2021, p. 7) 
• When dantrolene is	 unavailable, early 
warning signs must be identified with
prompt, effective therapies (Gong,
2021, p. 7) 
• Providers should advocate for 
dantrolene availability, even when 
succinylcholine is	 used	 without
volatile anesthetics as MH crisis may	




Association of the United States 
24/7	 Emergency MH Hotline 
1(800)MH-HYPER (644-9737) 
https://www.mhaus.org 
Signs & Symptoms 
Key	 Diagnostic Features
(Hopkins et al., 2021, p. 658) 
• Unexplained, unexpected rise in end-
tidal 	CO2 	(ETCO2) 
• Unexplained, unexpected increase in 
heart rate 
• Unexplained, unexpected increase in 
temperature 
• Unexplained, unexpected skeletal 
muscle rigidity 
Other Diagnostic Features
(Hopkins et al., 2021, p. 660) 
• Cardiac arrythmia 




• Disseminated intravascular 
coagulation (DIC) 
• Compartment syndrome 
• Masseter muscle rigidity 
Figure 1: Retrieved from https://www.capnoacademy.com/ 
Significance of Pathophysiology 
Although MH has a relatively low incidence, the MH crisis patient is at a
heightened risk for death	 and all clinicians – especially anesthesia	 providers – in 
the perioperative environment	 must	 be familiar with the signs, symptoms, and
protocols for treatment to reduce mortality. 
Pathogenesis: Excitation-
Contraction Coupling 
Figure 2: Retrieved from https://www.dovepress.com/cr_data/article_fulltext/s47000/47632/img/fig1.jpg 
MH is relatively rare, though
potentially fatal genetic condition that
requires prompt, effective treatment to
reduce mortality. This complexity 
requires pre-operative identification,
thorough history and physical, a team-
based treatment approach, and effective
communication. Anesthesia providers
are	 integral team members who must be	 
prepared with knowledge about MH and
need to be comfortable with the mixing
of dantrolene in a crisis. 
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